What is the dosage of Keytruda?

Keytruda is available in 2 dosages, including 25 mg/ml Injection 4 ml and 50 mg Injection

What does Keytruda treat?

Keytruda treats Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma, Hodgkin Disease, Melanoma, Ureteral Neoplasms, Urethral Neoplasms and Microsatellite Instability

What is Keytruda made of?

Keytruda contains pembrolizumab which is a Programmed Death Receptor-1 Blocking Antibody

How is Keytruda administered?

Keytruda is administered as a Injectable

What is Keytruda mechanism of action?

Keytruda mechanism of action is Programmed Death Receptor-1-directed Antibody Interactions

Dosage & Administration Biomarker testing Drug label Prior authorization Pharmacy Financial assistance

Patient education People also ask

Keytruda

(pembrolizumab)

4 ML pembrolizumab 25 MG/ML Injection [Keytruda]pembrolizumab 50 MG Injection [Keytruda]

NO BLACK BOX WARNING

Dosage & administration

* Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* NSCLC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* cHL or PMBCL: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* Urothelial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MSI-H or dMMR Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* MSI-H or dMMR CRC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MSI-H or dMMR Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Gastric Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Esophageal Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Cervical Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* HCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MCC: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* RCC: 200 mg every 3 weeks or 400 mg every 6 weeks as a single agent in the adjuvant setting, or in the advanced setting with either:
* axitinib 5 mg orally twice daily or
* lenvatinib 20 mg orally once daily.

* Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks with lenvatinib 20 mg orally once daily.
* TMB-H Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* cSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* TNBC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Administer KEYTRUDA as an intravenous infusion over 30 minutes after dilution.
* See Full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions.

biomarker testing

Keytruda clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Keytruda prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Keytruda prior authorization resources

Most recent Keytruda prior authorization forms

View By Payer

Updated: May 31, 2023Cigna - Keytruda Prior Authorization Form

Updated: May 24, 2023Aetna - Keytruda Prior Authorization Form

Updated: May 23, 2023Aetna - Medicare Part B Keytruda Prior Authorization Form

PDFCoverage Authorization Request

PDFCoverage Authorization Appeals

Learn More

Benefits investigation

PDF2022 Merck Access Program Enrollment Form

PDF2023 Merck Access Program Enrollment Form

PDFMerck Access Program - 2023 Healthcare Provider Enrollment Form

2022 Merck Access Program Electronic Enrollment Form

2023 Merck Access Program Electronic Enrollment Form

Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

pharmacy

Keytruda preferred pharmacy

OTHERPharmacy List

financial assistance

Keytruda financial assistance options

Co-pay savings program

commercial only

PDF2022 Merck Access Program Enrollment Form

PDF2023 Merck Access Program Enrollment Form

PDFMerck Access Program - 2023 Healthcare Provider Enrollment Form

2022 Merck Access Program Electronic Enrollment Form

2023 Merck Access Program Electronic Enrollment Form

Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form

OTHEREnroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

PDF2022 Merck Access Program Enrollment Form

PDF2023 Merck Access Program Enrollment Form

PDFMerck Access Program - 2023 Healthcare Provider Enrollment Form

2022 Merck Access Program Electronic Enrollment Form

2023 Merck Access Program Electronic Enrollment Form

Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form

OTHERMerck Patient Assistance Program Application

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.